Literature DB >> 7231916

Reducing side effects of carbonic anhydrase inhibitors.

P R Lichter.   

Abstract

Carbonic anhydrase inhibitor (CAI) side effects are common, but not well understood. Many ideas have surfaced on how to reduce these side effects, even though there is little scientific evidence to support some of the advice. One recommendation involves switching drugs when patients are intolerant of a particular CAI agent. This study included 44 glaucoma patients who needed a CAI drug. All patients were placed on acetazolamide tablets 250 mg qid. Of those who could not tolerate this drug (26 patients), 22 were switched to methazolamide. Half of these 22 (50%) were considered to have "severe" side effects to methazolamide, while 88% of them had "severe" side effects to acetazolamide. Reduction of intraocular pressure was similar on the two drugs. Other than switching drugs to reduce CAI side effects, one can try reduced dosages, a gradual dosage increase, and patience. Administering sodium bicarbonate or potassium, or taking the CAI drug with meals are unproven remedies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7231916     DOI: 10.1016/s0161-6420(81)35040-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

Review 1.  New insights into carbonic anhydrase inhibition, vasodilation, and treatment of hypertensive-related diseases.

Authors:  Erik R Swenson
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

2.  Laser trabeculoplasty and decay effects in glaucoma patients.

Authors:  A I Fink; A J Jordan
Journal:  J R Soc Med       Date:  1984-02       Impact factor: 5.344

Review 3.  The role of carbonic anhydrase inhibitors in the management of macular edema.

Authors:  T J Wolfensberger
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

4.  Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume.

Authors:  T J Wolfensberger; A V Dmitriev; V I Govardovskii
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

Review 5.  Treatment Updates for Neuromuscular Channelopathies.

Authors:  Nantaporn Jitpimolmard; Emma Matthews; Doreen Fialho
Journal:  Curr Treat Options Neurol       Date:  2020-08-22       Impact factor: 3.598

Review 6.  Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Authors:  R I Henkin
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

7.  Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management.

Authors:  Matthew J Thurtell; Michael Wall
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

8.  Acute bilateral angle closure glaucoma induced by methazolamide.

Authors:  Ahmad A Aref; Fouad E Sayyad; Bernadete Ayres; Richard K Lee
Journal:  Clin Ophthalmol       Date:  2013-02-11

9.  Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence.

Authors:  Christopher N Schmickl; Robert L Owens; Jeremy E Orr; Bradley A Edwards; Atul Malhotra
Journal:  BMJ Open Respir Res       Date:  2020-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.